Veriphi is an innovative New Zealand company based in Devonport, Auckland, formed in 2002, to use rapidly evolving spectral technology to analyse fluids in medical applications. The company began by experimenting with spectroscopy for point-of-care blood analysis. By 2009 Veriphi had shifted its focus to the less-challenging application of IV drug identity and concentration verification for medication error prevention. 

By 2016 Veriphi had pioneered a technique to verify multiple drugs across multiple cuvettes. It was the first comprehensive demonstration of the technology’s ability to correctly verify the identity of a suite of drugs, despite each drug being presented in multiple cuvettes. This was a critical initial proof of concept for verifying a drug inside an IV bag or syringe.

On the advice of industry partners and the US Food and Drug Administration (FDA), Veriphi chose to focus on oncology drugs in compounding pharmacies as its first target market application. Pharmacy use did not require medical device approvals and offered the most efficient market compliance pathway. 

Oncology drugs are a use case where the consequences of error can have a high impact on patient outcomes. The technical challenges are large such that in resolving these issues, Veriphi has built a significant patent portfolio, which includes eight granted US patents and 22 global patents.

Veriphi is working closely with clinical partners in New Zealand and abroad to commercialise its solution. Veriphi’s vision is to make IV cancer therapy not only safer but more accurate.